A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of JNJ-64304500 in Subjects with Moderately to Severely Active Crohn’s Disease
The experimental drugs used in this study are called JNJ 64304500 and ustekinumab. The purpose of this study is to see if if JNJ 64304500 is useful for treating patients with moderately to severely active Crohn’s Disease. ...